Ponatinib, a third-generation tyrosine kinase inhibitor, is effective in patients with chronic myeloid leukemia (CML), particularly in cases of resistance or BCR::ABL1 T315I mutation. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.